Brief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
30/09/2026 23:31
BRIEF-Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa Oct 1 (Reuters) - Corvus Pharmaceuticals, Inc. CRVS.O:
CORVUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL OF SOQUELITINIB FOR PATIENTS WITH HIDRADENITIS SUPPURATIVA
CORVUS PHARMACEUTICALS, - PRIMARY ENDPOINT IS SAFETY AND TOLERABILITY; KEY EFFICACY ENDPOINT IS HISCR 50/75 AT WEEK 12
Source text: ID:nGNX7Ms8pR
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental